Abstract
Recently, multiple clinical trials demonstrated neoadjuvant chemoimmunotherapy is a promising treatment option for resectable non-small-cell lung cancer (NSCLC). However, there is still limited evidence for using chemoimmunotherapy as neoadjuvant treatment in potentially resectable stage III squamous NSCLC. TACT (NCT05024266) is a phase II, open label, single arm trial evaluating the efficacy and safety of tislelizumab(Tis) plus chemotherapy(CT) as neoadjuvant treatment for potentially resectable stage IIIA-IIIB(N2) squamous NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
